Iterum Therapeutics (ITRM)
(Delayed Data from NSDQ)
$0.70 USD
-0.02 (-2.58%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $0.71 +0.01 (2.10%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ITRM 0.70 -0.02(-2.58%)
Will ITRM be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ITRM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ITRM
ITRM Posts Updates From FDA Advisory Meeting for UTI Drug, Stock Down
ITRM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for ITRM
Q2 2025 Iterum Therapeutics PLC Earnings Call Transcript
Iterum Therapeutics (ITRM) Financial Outlook for 2025
ITRM: Iterum Therapeutics to Launch New Antibiotic for UTIs
Iterum Therapeutics Reports Second Quarter 2025 Financial Results | ITRM Stock News
Iterum Therapeutics Non-GAAP EPS of -$0.13